Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
Benzinga Newsdesk 17 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.